Document Detail

Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
MedLine Citation:
PMID:  19584744     Owner:  NLM     Status:  MEDLINE    
We present the case of a 60-year-old lady who was treated with chemotherapy for myeloma. Following initiation of bortezomib, she developed heart failure which was associated with a reduction in left ventricular systolic function. A gadolinium enhanced cardiovascular magnetic resonance scan demonstrated midwall hyperenhancement consistent with midwall fibrosis.
Paul W X Foley; Malcolm S Hamilton; Francisco Leyva
Related Documents :
24794044 - Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treat...
16288714 - Tnf-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonisch...
19945184 - Myocarditis in children and detection of viruses in myocardial tissue: implications for...
19429974 - Diagnostic exercise: myocarditis due to histophilus somni in feedlot and backgrounded c...
19046784 - Endogenous catecholamine levels and function of the systemic right ventricle following ...
24569834 - Mir-29b as a therapeutic agent for angiotensin ii-induced cardiac fibrosis by targeting...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  11     ISSN:  1558-2035     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-03-30     Completed Date:  2010-06-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  386-8     Citation Subset:  IM    
Department of Cardiology, Good Hope Hospital, Sutton Coldfield, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Boronic Acids / adverse effects*
Fatal Outcome
Gadolinium / diagnostic use*
Heart Failure / chemically induced*,  pathology
Magnetic Resonance Imaging
Middle Aged
Multiple Myeloma / drug therapy
Myocardium / pathology
Pyrazines / adverse effects*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Boronic Acids; 0/Pyrazines; 0/bortezomib; 7440-54-2/Gadolinium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report.
Next Document:  How long does it take to make an accurate diagnosis in an epilepsy monitoring unit?